Laith Alzweri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laith Alzweri has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Corey Able
Division of Urology, Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, USA
3 shared publications- Joseph Sonstein
Division of Urology, Department of Surgery, University of Texas Medical Branch, 301 University Blvd, Galveston, Texas 77555-0540, USA
3 shared publications Ali A. Nasrallah
Division of Urology, Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, USA
2 shared publications- Andrew T. Gabrielson
Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL, USA
2 shared publications Clemens An
The Robert Larner M.D. College of Medicine, The University of Vermont, Burlington, USA
2 shared publications- Kevin Vu
Division of Urology, Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, USA
2 shared publications
Latest Publications
- 9 July 2024
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (6) , 471-476
A population analysis of delayed ejaculation using a claims database: characteristics and national trends in prevalence, incidence, and pharmacotherapy
We investigated the prevalence, incidence, and rates of pharmacological treatment of delayed ejaculation using the TriNetX Diamond Network. We included all men evaluated in the inpatient, outpatient, and emergency settings. Prevalence was determined by comparing the number of men diagnosed with delayed ejaculation to the entire population. Incidence was determined by comparing the number of men diagnosed with delayed ejaculation without a prior diagnosis to the overall population without a prior diagnosis. Rates of pharmacologic treatment were calculated by comparing the number of men who received a prescription to the total number of men with delayed ejaculation. Trends in prevalence and incidence were compared using six-month intervals, while trends in pharmacologic treatment were compared using one-year intervals. A total of 23,164 adult males were diagnosed with delayed ejaculation from 2013 to 2019. During the final six-month interval (July to December 2019), 2,747 of 16,496,744 men received a delayed ejaculation diagnosis, and 1,375 of 16,488,270 men without a prior diagnosis were diagnosed with delayed ejaculation. In 2019, only 916 of 4,733 (19.4%) men diagnosed with delayed ejaculation received any prescription, with the most common being testosterone (9.5%), bupropion (6.6%), and buspirone (2.3%). Prevalence, incidence and pharmacologic treatment all had increasing trends.
- 9 July 2024
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (6) , 471-476
A population analysis of delayed ejaculation using a claims database: characteristics and national trends in prevalence, incidence, and pharmacotherapy
We investigated the prevalence, incidence, and rates of pharmacological treatment of delayed ejaculation using the TriNetX Diamond Network. We included all men evaluated in the inpatient, outpatient, and emergency settings. Prevalence was determined by comparing the number of men diagnosed with delayed ejaculation to the entire population. Incidence was determined by comparing the number of men diagnosed with delayed ejaculation without a prior diagnosis to the overall population without a prior diagnosis. Rates of pharmacologic treatment were calculated by comparing the number of men who received a prescription to the total number of men with delayed ejaculation. Trends in prevalence and incidence were compared using six-month intervals, while trends in pharmacologic treatment were compared using one-year intervals. A total of 23,164 adult males were diagnosed with delayed ejaculation from 2013 to 2019. During the final six-month interval (July to December 2019), 2,747 of 16,496,744 men received a delayed ejaculation diagnosis, and 1,375 of 16,488,270 men without a prior diagnosis were diagnosed with delayed ejaculation. In 2019, only 916 of 4,733 (19.4%) men diagnosed with delayed ejaculation received any prescription, with the most common being testosterone (9.5%), bupropion (6.6%), and buspirone (2.3%). Prevalence, incidence and pharmacologic treatment all had increasing trends.
- Open Access
- 19 June 2024
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (6) , 446-447
Hard-Flaccid syndrome: a survey of sexual medicine practitioners’ knowledge and experience
Hard-flaccid syndrome (HFS) is a poorly understood condition of male sexual dysfunction (MSD) that has more recently become a new topic of discussion in online forums and sexual medicine conferences. There has been limited research looking into HFS and consequently there are no evidence-based guidelines for its work-up and management. In order to identify the current level of understanding of HFS in the sexual medicine community, a survey was distributed at a national urologic conference focusing on pertinent management strategies employed by practitioners, and their own thoughts on HFS. This showed that nearly one-third of those surveyed had never seen HFS in their practice. Of those that had, diagnosis was mainly made via clinical history as well as patient self-diagnosis. Additionally, only about half of the respondents who had seen HFS were confident in its legitimacy as a real medical syndrome. This analysis is one of the first of its kind, and highlights the ongoing lack of familiarity of HFS among the sexual medicine community. There were limitations, most notably its survey format as well as low sample size, however, it importantly emphasizes the critical need for continued education and research into HFS to improve diagnostic accuracy, enhance patient care, and develop effective treatment strategies.
- 19 June 2024
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (6) , 446-447
Open AccessHard-Flaccid syndrome: a survey of sexual medicine practitioners’ knowledge and experience
Hard-flaccid syndrome (HFS) is a poorly understood condition of male sexual dysfunction (MSD) that has more recently become a new topic of discussion in online forums and sexual medicine conferences. There has been limited research looking into HFS and consequently there are no evidence-based guidelines for its work-up and management. In order to identify the current level of understanding of HFS in the sexual medicine community, a survey was distributed at a national urologic conference focusing on pertinent management strategies employed by practitioners, and their own thoughts on HFS. This showed that nearly one-third of those surveyed had never seen HFS in their practice. Of those that had, diagnosis was mainly made via clinical history as well as patient self-diagnosis. Additionally, only about half of the respondents who had seen HFS were confident in its legitimacy as a real medical syndrome. This analysis is one of the first of its kind, and highlights the ongoing lack of familiarity of HFS among the sexual medicine community. There were limitations, most notably its survey format as well as low sample size, however, it importantly emphasizes the critical need for continued education and research into HFS to improve diagnostic accuracy, enhance patient care, and develop effective treatment strategies.
- 22 May 2024
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (4) , 315-319
Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study
Semaglutide was approved in June 2021 for weight loss in non-diabetic, obese patients. While package inserts include sexual dysfunction as a side effect, no study has assessed the degree of this risk. The objective of our study is to assess the risk of developing erectile dysfunction after semaglutide is prescribed for weight loss in obese, non-diabetic men. The TriNetX Research database was used to identify men without a diagnosis of diabetes ages 18 to 50 with BMI > 30 who were prescribed semaglutide after June 1st, 2021. Men were excluded if they had a prior erectile dysfunction diagnosis, any phosphodiesterase-5 inhibitors prescription, intracavernosal injections, penile prosthesis placement, history of testosterone deficiency, testosterone prescription, pelvic radiation, radical prostatectomy, pulmonary hypertension, or were deceased. We further restricted our cohort to non-diabetic, obese men by excluding men with a prior diabetes mellitus diagnosis, a hemoglobin A1c > 6.5%, or having ever received insulin or metformin. Men were then stratified into cohorts of those that did and did not receive a semaglutide prescription. The primary outcome was the risk of new ED diagnosis and/or new prescription of phosphodiesterase type 5 inhibitors at least one month after prescription of semaglutide. The secondary outcome was risk of testosterone deficiency diagnosis. Risk was reported using risk ratios with 95% confidence intervals (95% CI). 3,094 non-diabetic, obese men ages 18–50 who received a prescription of semaglutide were identified and subsequently matched to an equal number cohort of non-diabetic, obese men who never received a prescription of semaglutide. After matching, average age at index prescription for non-diabetic, obese men was 37.8 ± 7.8 and average BMI at index prescription was 38.6 ± 5.6. Non-diabetic men prescribed semaglutide were significantly more likely to develop erectile dysfunction and/or were prescribed phosphodiesterase type 5 inhibitors (1.47% vs 0.32%; RR: 4.5; 95% CI [2.3, 9.0]) and testosterone deficiency (1.53% vs 0.80%; RR: 1.9; 95% CI [1.2, 3.1]) when compared to the control cohort of non-diabetic men who never received a semaglutide prescription.
- 22 May 2024
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (4) , 315-319
Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study
Semaglutide was approved in June 2021 for weight loss in non-diabetic, obese patients. While package inserts include sexual dysfunction as a side effect, no study has assessed the degree of this risk. The objective of our study is to assess the risk of developing erectile dysfunction after semaglutide is prescribed for weight loss in obese, non-diabetic men. The TriNetX Research database was used to identify men without a diagnosis of diabetes ages 18 to 50 with BMI > 30 who were prescribed semaglutide after June 1st, 2021. Men were excluded if they had a prior erectile dysfunction diagnosis, any phosphodiesterase-5 inhibitors prescription, intracavernosal injections, penile prosthesis placement, history of testosterone deficiency, testosterone prescription, pelvic radiation, radical prostatectomy, pulmonary hypertension, or were deceased. We further restricted our cohort to non-diabetic, obese men by excluding men with a prior diabetes mellitus diagnosis, a hemoglobin A1c > 6.5%, or having ever received insulin or metformin. Men were then stratified into cohorts of those that did and did not receive a semaglutide prescription. The primary outcome was the risk of new ED diagnosis and/or new prescription of phosphodiesterase type 5 inhibitors at least one month after prescription of semaglutide. The secondary outcome was risk of testosterone deficiency diagnosis. Risk was reported using risk ratios with 95% confidence intervals (95% CI). 3,094 non-diabetic, obese men ages 18–50 who received a prescription of semaglutide were identified and subsequently matched to an equal number cohort of non-diabetic, obese men who never received a prescription of semaglutide. After matching, average age at index prescription for non-diabetic, obese men was 37.8 ± 7.8 and average BMI at index prescription was 38.6 ± 5.6. Non-diabetic men prescribed semaglutide were significantly more likely to develop erectile dysfunction and/or were prescribed phosphodiesterase type 5 inhibitors (1.47% vs 0.32%; RR: 4.5; 95% CI [2.3, 9.0]) and testosterone deficiency (1.53% vs 0.80%; RR: 1.9; 95% CI [1.2, 3.1]) when compared to the control cohort of non-diabetic men who never received a semaglutide prescription.
- Open Access
- 22 November 2023
- Published by Springer Nature in Research Square
A Population Analysis of Delayed Ejaculation Using a Claims Database: Characteristics and National Trends in Prevalence, Incidence, and Pharmacotherapy
Delayed ejaculation (DE) is rare disorder of sexual function reported to affect between 1-5% of men. However, due to the lack of a standard definition, the true prevalence, incidence, and treatment trends remain unclear. Herein, we assess the trends in prevalence and incidence of DE diagnosis as well as the medications and comorbidities in men when diagnosed with DE and treatment patterns using a large claims database. The TriNetX Diamond database was queried to identify adult males diagnosed with DE. Prevalence was determined by comparing men with a diagnosis of DE to the total population of men evaluated in the inpatient, outpatient, and emergency settings in six-month intervals within the database. Similarly, incidence was determined by comparing men with a new diagnosis to the total population of men without a previous diagnosis. Pharmacotherapy rates were calculated by comparing the number of men receiving a prescription to the total number of men in one-year intervals. We identified 23,164 men with a diagnosis of DE. In the final period, 2,747 (0.02%) men were diagnosed with DE and 1,375 (0.01%) received a new diagnosis of DE, with prevalence and incidence increasing over time. The most common medications prescribed in the final period were testosterone (9.5%), bupropion (6.6%), and buspirone (2.3%). Additionally, 916 (19.4%) received any prescription, with the rates of these medications increasing consistently over time. Delayed ejaculation is rarely diagnosed but has increasing prevalence. Rates of pharmacotherapy remain low. Further work is needed to investigate first-line medical therapy if behavioral modifications and psychotherapy fail.
- 22 November 2023
- Published by Springer Nature in Research Square
Open AccessA Population Analysis of Delayed Ejaculation Using a Claims Database: Characteristics and National Trends in Prevalence, Incidence, and Pharmacotherapy
Delayed ejaculation (DE) is rare disorder of sexual function reported to affect between 1-5% of men. However, due to the lack of a standard definition, the true prevalence, incidence, and treatment trends remain unclear. Herein, we assess the trends in prevalence and incidence of DE diagnosis as well as the medications and comorbidities in men when diagnosed with DE and treatment patterns using a large claims database. The TriNetX Diamond database was queried to identify adult males diagnosed with DE. Prevalence was determined by comparing men with a diagnosis of DE to the total population of men evaluated in the inpatient, outpatient, and emergency settings in six-month intervals within the database. Similarly, incidence was determined by comparing men with a new diagnosis to the total population of men without a previous diagnosis. Pharmacotherapy rates were calculated by comparing the number of men receiving a prescription to the total number of men in one-year intervals. We identified 23,164 men with a diagnosis of DE. In the final period, 2,747 (0.02%) men were diagnosed with DE and 1,375 (0.01%) received a new diagnosis of DE, with prevalence and incidence increasing over time. The most common medications prescribed in the final period were testosterone (9.5%), bupropion (6.6%), and buspirone (2.3%). Additionally, 916 (19.4%) received any prescription, with the rates of these medications increasing consistently over time. Delayed ejaculation is rarely diagnosed but has increasing prevalence. Rates of pharmacotherapy remain low. Further work is needed to investigate first-line medical therapy if behavioral modifications and psychotherapy fail.
- 29 December 2022
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 36 (4) , 385-393
Association of total and free testosterone with cardiovascular disease in a nationally representative sample of white, black, and Mexican American men
Associations of total testosterone (T) and calculated free T with cardiovascular disease (CVD) remain poorly understood. Particularly how these associations vary according to race and ethnicity in a nationally representative sample of men. Data included 7058 men (≥20 years) from NHANES. CVD was defined as any reported diagnosis of heart failure (HF), coronary artery disease (CAD), myocardial infarction (MI), and stroke. Total T (ng/mL) was obtained among males who participated in the morning examination. Weighted multivariable-adjusted logistic regression models were conducted. We found associations of low T (OR = 1.57, 95% CI = 1.17–2.11), low calculated free T (OR = 1.53, 95% CI = 1.10–2.17), total T (Q1 vs Q5), and calculated free T (Q1 vs Q5) with CVD after adjusting for estradiol and SHBG. In disease specific analysis, low T increased prevalence of MI (OR = 1.72, 95% CI = 1.08–2.75) and HF (OR = 1.74, 95% CI = 1.08–2.82), but a continuous increment of total T reduced the prevalence of CAD. Similar inverse associations were identified among White and Mexican Americans, but not Blacks (OR = 0.93, 95% CI = 0.49–1.76). Low levels of T and calculated free T were associated with an increased prevalence of overall CVD and among White and Mexican Americans. Associations remained in the same direction with specific CVD outcomes in the overall population.
- 29 December 2022
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 36 (4) , 385-393
Association of total and free testosterone with cardiovascular disease in a nationally representative sample of white, black, and Mexican American men
Associations of total testosterone (T) and calculated free T with cardiovascular disease (CVD) remain poorly understood. Particularly how these associations vary according to race and ethnicity in a nationally representative sample of men. Data included 7058 men (≥20 years) from NHANES. CVD was defined as any reported diagnosis of heart failure (HF), coronary artery disease (CAD), myocardial infarction (MI), and stroke. Total T (ng/mL) was obtained among males who participated in the morning examination. Weighted multivariable-adjusted logistic regression models were conducted. We found associations of low T (OR = 1.57, 95% CI = 1.17–2.11), low calculated free T (OR = 1.53, 95% CI = 1.10–2.17), total T (Q1 vs Q5), and calculated free T (Q1 vs Q5) with CVD after adjusting for estradiol and SHBG. In disease specific analysis, low T increased prevalence of MI (OR = 1.72, 95% CI = 1.08–2.75) and HF (OR = 1.74, 95% CI = 1.08–2.82), but a continuous increment of total T reduced the prevalence of CAD. Similar inverse associations were identified among White and Mexican Americans, but not Blacks (OR = 0.93, 95% CI = 0.49–1.76). Low levels of T and calculated free T were associated with an increased prevalence of overall CVD and among White and Mexican Americans. Associations remained in the same direction with specific CVD outcomes in the overall population.
- 1 April 2022
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 19 (Supplement) , S98-S99
194 Environmental Toxicants and Male Sexual Dysfunctions
Introduction: Understanding how substances in the environment impact sexual function is a broad and ever-expanding field. While some toxicants are well understood to disrupt the male sexual response cycle or impact the ejaculation pathway, other are just being understood. Objective: We reviewed current articles detailing how heavy metals, industrial chemicals, pesticides, lifestyle and behaviors, climate, and radiation affect the male sexual function and the suspected mechanisms these toxicants have as sexual function disruptors. Methods: We used SCOPUS and PubMed to review literature from 2016-2020 pertaining to the topics of environmental toxicants including those relating to heavy metals, industrial chemicals, pesticides, life style and behavioral exposures, climate, and radiation. Studies were also included if the paper included research on the toxicant specified and the authors hypothesized on the pathophysiological effect the toxin had on the male sexual response cycle. Studies were also included if the research demonstrated that the toxicant was shown to have no impact on male sexual health or a mixed conclusion. Results: A total of 109 papers were collected and 79 were analyzed in this review. While every one of these categories had articles that were inconclusive or did not find that the toxicants had a significant effect on male sexual function, the majority of studies showed that heavy metals, industrial chemicals, pesticides, and climate had a positive correlation between male sexual dysfunction and exposure to these toxicants. Lifestyle and behaviors showed a positive correlation, but the studies done on bicycling and diet were not as numerous as in the other categories. Radiation was the only category that did not have a definitive answer for whether it causes male sexual dysfunction or not. Our study identified that heavy metals, industrial chemicals, and pesticides effected the hormones involved in sexual function and decreased the quality of sperm in those studied. Sperm quality was also decreased in those exposed to climate and radiation. Impairment and injury to sexual organs caused by the toxicants were observed in both the industrial chemical and climate category. The increased risks these toxicants impose on male sexual function is shown in table 1. Conclusions: These results show that the field of research devoted to understanding the connection between many of these agents and male sexual function has grown in recent years, but still needs focus and attention brought to it. Disclosure: No
- 1 April 2022
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 19 (Supplement) , S98-S99
194 Environmental Toxicants and Male Sexual Dysfunctions
Introduction: Understanding how substances in the environment impact sexual function is a broad and ever-expanding field. While some toxicants are well understood to disrupt the male sexual response cycle or impact the ejaculation pathway, other are just being understood. Objective: We reviewed current articles detailing how heavy metals, industrial chemicals, pesticides, lifestyle and behaviors, climate, and radiation affect the male sexual function and the suspected mechanisms these toxicants have as sexual function disruptors. Methods: We used SCOPUS and PubMed to review literature from 2016-2020 pertaining to the topics of environmental toxicants including those relating to heavy metals, industrial chemicals, pesticides, life style and behavioral exposures, climate, and radiation. Studies were also included if the paper included research on the toxicant specified and the authors hypothesized on the pathophysiological effect the toxin had on the male sexual response cycle. Studies were also included if the research demonstrated that the toxicant was shown to have no impact on male sexual health or a mixed conclusion. Results: A total of 109 papers were collected and 79 were analyzed in this review. While every one of these categories had articles that were inconclusive or did not find that the toxicants had a significant effect on male sexual function, the majority of studies showed that heavy metals, industrial chemicals, pesticides, and climate had a positive correlation between male sexual dysfunction and exposure to these toxicants. Lifestyle and behaviors showed a positive correlation, but the studies done on bicycling and diet were not as numerous as in the other categories. Radiation was the only category that did not have a definitive answer for whether it causes male sexual dysfunction or not. Our study identified that heavy metals, industrial chemicals, and pesticides effected the hormones involved in sexual function and decreased the quality of sperm in those studied. Sperm quality was also decreased in those exposed to climate and radiation. Impairment and injury to sexual organs caused by the toxicants were observed in both the industrial chemical and climate category. The increased risks these toxicants impose on male sexual function is shown in table 1. Conclusions: These results show that the field of research devoted to understanding the connection between many of these agents and male sexual function has grown in recent years, but still needs focus and attention brought to it. Disclosure: No
- Open Access
- 3 July 2021
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 19 (3) , 363-369
Peyronie’s disease – outcomes of collagenaseclostridium histolyticuminjection: A systematic review
To review recent literature pertaining to collagenase clostridium histolyticum (CCh)and other intralesional (IL) therapies for the treatment of Peyronie’s disease (PD). A systematic search of liter...
- 3 July 2021
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 19 (3) , 363-369
Open AccessPeyronie’s disease – outcomes of collagenaseclostridium histolyticuminjection: A systematic review
To review recent literature pertaining to collagenase clostridium histolyticum (CCh)and other intralesional (IL) therapies for the treatment of Peyronie’s disease (PD). A systematic search of liter...
- Open Access
- 1 January 2018
- Published by XMLink in The World Journal of Men's Health
- Vol. 36 (1) , 4-14
Role of Penile Prosthesis in Priapism: A Review
Reddy AG, et al. World J Mens Health. 2017 Sep;35:e21. https://doi.org/10.5534/wjmh.17040
- 1 January 2018
- Published by XMLink in The World Journal of Men's Health
- Vol. 36 (1) , 4-14
Open AccessRole of Penile Prosthesis in Priapism: A Review
Reddy AG, et al. World J Mens Health. 2017 Sep;35:e21. https://doi.org/10.5534/wjmh.17040
- Open Access
- 1 January 2017
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 35 (3) , 134-145
Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option
Gabrielson AT, et al. World J Mens Health. 2017 Sep;35:e7. /Synapse/10.5534/wjmh.2017.35.e7
- 1 January 2017
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 35 (3) , 134-145
Open AccessCollagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option
Gabrielson AT, et al. World J Mens Health. 2017 Sep;35:e7. /Synapse/10.5534/wjmh.2017.35.e7